Atrial Natriuretic Peptide vs Nesiritide — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Atrial natriuretic peptide (ANP) is a 28-amino acid cardiac hormone secreted by atrial cardiomyocytes in response to increased atrial wall stretch from volume overload or pressure elevation. ANP acts on NPR-A receptors (identical to those targeted by nesiritide/BNP) to produce na...
Calculate Atrial Natriuretic Peptide dose →Nesiritide is a recombinant form of human B-type natriuretic peptide (BNP), approved for the intravenous treatment of acutely decompensated heart failure (ADHF) in patients with dyspnea at rest or with minimal activity. Released endogenously by ventricular cardiomyocytes in respo...
Calculate Nesiritide dose →| Parameter | Atrial Natriuretic Peptide | Nesiritide |
|---|---|---|
| Category | Cardiovascular / Natriuretic Peptide | Cardiovascular / Natriuretic Peptide |
| Research | Approved (Japan); Research (US/EU) | FDA Approved |
| Half-Life | 2-3 minutes (plasma) | ~18 minutes (initial phase); ~2 hours (terminal) |
| Typical Dose | Carperitide: 0.025-0.1 mcg/kg/min IV infusion | 2 mcg/kg IV bolus, then 0.01 mcg/kg/min continuous infusion |
| Frequency | Continuous IV infusion for ADHF (Japan) | Continuous infusion for ADHF hospitalization |
| Route | Endogenous (atrial cardiomyocytes); IV infusion (carperitide) | Intravenous infusion |
| FDA Status | Not FDA approved; carperitide approved in Japan for ADHF | Approved (acute decompensated heart failure) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.